Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Oct 10:10:1275450.
doi: 10.3389/fnut.2023.1275450. eCollection 2023.

Combined effect of serum carcinoembryonic antigen and hepatic steatosis on new-onset ischemic heart disease among middle-aged and older Korean adults: a cohort study

Ji Won Kwak  1 , Yong Jae Lee  1 , Byoungjin Park  1 , Dong Hyuk Jung  1
Affiliations

Combined effect of serum carcinoembryonic antigen and hepatic steatosis on new-onset ischemic heart disease among middle-aged and older Korean adults: a cohort study

Ji Won Kwak et al. Front Nutr. .

Abstract

Background: Carcinoembryonic antigen (CEA) is a commonly used tumor marker in cancer screening. However, it has also been associated with metabolic alterations. Hepatic steatosis, the accumulation of fat in liver cells, is associated with various cardiovascular risk factors. This study investigated the risk of ischemic heart disease (IHD) in individuals with elevated CEA levels, hepatic steatosis, and their co-occurrence.

Methods: The study cohort comprised 5,580 Korean adults who underwent health examinations between November 2006 and June 2010. Data regarding baseline CEA levels, hepatic steatosis status, and development of IHD were collected. Hepatic steatosis was defined as more than two findings: deep attenuation, vascular blurring, and increased liver echogenicity on abdominal ultrasound. Participants were divided into four groups based on their CEA and hepatic steatosis status: no hepatic steatosis and low CEA (group 1), no hepatic steatosis and elevated CEA (group 2), low CEA and hepatic steatosis (group 3), and elevated CEA and hepatic steatosis (group 4).

Results: A total of 226 (4.1%) participants developed IHD during the follow-up period. Participants with elevated CEA levels and hepatic steatosis (group 4) had the highest cumulative incidence of IHD in comparison to other groups (p < 0.001). The combined effect of elevated CEA levels and hepatic steatosis showed significantly greater area under the receiver operating characteristic curve than hepatic steatosis alone (p < 0.001). Furthermore, participants with elevated CEA and hepatic steatosis (group 4) had higher risk of developing IHD compared to those with low CEA and no hepatic steatosis (group 1) (hazard ratio: 1.63, 95% confidence interval: 1.04-2.55, p = 0.034).

Conclusion: Co-occurrence of elevated CEA levels and hepatic steatosis increases the risk of IHD. Comprehensive risk assessment is crucial to guide interventions and improve cardiovascular health in individuals with both the conditions.

Keywords: carcinoembryonic antigen; cohort study; hepatic steatosis; ischemic heart disease; middle-aged and older adults.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart depicting selection of the study population.
Figure 2
Figure 2
Violin plots with embedded box plots according to CEA and hepatic steatosis. CEA, carcinoembryonic antigen. Black dotted lines indicate the maximum and minimum CEA values of each group.
Figure 3
Figure 3
Cox regression survival curve for incidence of ischemic heart disease.
Figure 4
Figure 4
Combined effect of carcinoembryonic antigen and hepatic steatosis on incident ischemic heart disease. Age-and sex-adjusted Cox proportional hazards regression model analysis. **p < 0.001.
Figure 5
Figure 5
Age-and sex-adjusted hazard ratios (95% confidence intervals) for incident ischemic heart disease according to carcinoembryonic antigen and hepatic steatosis.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Hall C, Clarke L, Pal A, Buchwald P, Eglinton T, Wakeman C, et al. . A review of the role of carcinoembryonic antigen in clinical practice. Ann Coloproctol. (2019) 35:294–305. doi: 10.3393/ac.2019.11.13, PMID: - DOI - PMC - PubMed
    1. Zhang Y, Yang J, Li H, Wu Y, Zhang H, Chen W. Tumor markers CA19-9, CA242 and CEA in the diagnosis of pancreatic cancer: a meta-analysis. Int J Clin Exp Med. (2015) 8:11683–91. PMID: - PMC - PubMed
    1. Shen M, Wang H, Wei K, Zhang J, You C. Five common tumor biomarkers and CEA for diagnosing early gastric cancer: a protocol for a network meta-analysis of diagnostic test accuracy. Medicine. (2018) 97:e0577. doi: 10.1097/md.0000000000010577, PMID: - DOI - PMC - PubMed
    1. Choi MS, Huh JW, Shin JK, Park YA, Cho YB, Kim HC, et al. . Prognostic factors and treatment of recurrence after local excision of rectal Cancer. Yonsei Med J. (2021) 62:1107–16. doi: 10.3349/ymj.2021.62.12.1107, PMID: - DOI - PMC - PubMed
    1. Chung S, Lee Y, Roh EY. HbA1c showed a positive association with carcinoembryonic antigen (CEA) level in only diabetes, not prediabetic or normal individuals. J Clin Lab Anal. (2019) 33:e22900. doi: 10.1002/jcla.22900, PMID: - DOI - PMC - PubMed

LinkOut - more resources